Go Back

//COAs white paper// Why are they important criteria in the evaluation of dossiers by health authorities?

Diverse elements have combined in recent years to make Clinical Outcome Assessments (COAs), and particularly Patient Reported Outcomes (PROs), important criteria for various health authorities in the evaluation of new therapeutic strategies. So Olivier Chassany has written this COAs white paper in order to deal with their importance in the evaluation by health authorities.

Why is this and what are the consequences for evaluation of new drugs in clinical development programs? When should COA endpoints be considered for inclusion in a new drug development program?

By Olivier Chassany, Professor of PROs & Clinical Endpoints research at the University Paris-Diderot, France


COAs white paper health authorities


Last update : 7 December 2016


  • 14 June
    DIA 2020 - June 14-18 - Washington, DC - Booth #239 - Schedule a meeting with Kayentis
  • 13 September
    SCDM - Sept 13-16 - San Antonio, USA - Booth #514 - Schedule a meeting with Kayentis
  • 26 October
    OCT Europe 2020 - October 26-27 - Paris, France - Booth #83 - Schedule a meeting with Kayentis
  • 02 November
    Clinical Trials Europe - Nov 2-4 - Amsterdam, The Netherlands - Booth #88 - Schedule a meeting with Kayentis     Clinical Trials Europe
  • Follow us

    Download our brochure